『药品』中重度斑块状银屑病成人患者福音!全球首个靶向白细胞介素23抑制剂在中国上市( 二 )


【『药品』中重度斑块状银屑病成人患者福音!全球首个靶向白细胞介素23抑制剂在中国上市】[3] BlauveltA, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23monoclonal antibody, compared with adalimumab for the continuous treatment ofpatients with moderate to severe psoriasis: Results from the phase III, double-blind,placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol.2017;76:405-417.
[4] Reich Kand Armstrong A.W, et al. J Am Acad Dermatol 2017;76(3):418–431.
『药品』中重度斑块状银屑病成人患者福音!全球首个靶向白细胞介素23抑制剂在中国上市
本文插图